Insight

Yan Leyfman

Jun 6, 2025, 16:15

Yan Leyfman: IFN-γR Knockout Improves CD28 CAR T Cell Function in Tumor Models

Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn:

“New findings from Dr. Marcela Maus and team at Mass General Hospital reveal a surprising twist in CAR T-cell therapy:

While IFN-γ is often seen as a key player in immunotherapy, this study shows it may actually induce apoptosis in CD28-based CAR T cells, limiting their persistence and efficacy.

Knockout of IFN-γ receptor (IFN-γR) enhanced CAR T cell survival, memory, and anti-tumor activity – especially in solid tumors where CAR T success has been more elusive.

IFN-γR KO led to:

Better tumor control

Longer survival

Durable immune memory

Enhanced tumor cell apoptosis

This could mark a major advance in optimizing CAR T design for both liquid and solid cancers.”

Title: IFN-γ–resistant CD28 CAR T cells demonstrate increased survival, efficacy, and durability in multiple murine tumor models

Journal: Science Translational Medicine

Authors: Stefanie R. Bailey, Hana N. Takei, Giulia Escobar, Michael C. Kann, Amanda A. Bouffard, Tamina Kienka, Valentina M. Supper, Alexander Armstrong, Diego Salas-Benito, Merle K. Phillips, Filippo Birocchi, Sonika Vatsa, Harrison Silva, Irene Scarfò, Marc Wehrli, Korneel Grauwet, Eli P. Darnell, Charlotte E. Graham, Mark B. Leick, Felix Korell, Trisha R. Berger, Marcela V. Maus

Read the full article.

CAR T Cell

More posts featuring Yan Leyfman on OncoDaily.

Alexander Armstrong Amanda A. Bouffard cancer CAR T-CELL CAR T-cell therapy Charlotte E. Graham Diego Salas-Benito Eli P. Darnell Felix Korell Filippo Birocchi Giulia Escobar Hana N. Takei Harrison Silva IFN-γ immunotherapy Irene Scarfò Korneel Grauwet liquid cancers Marc Wehrli Marcela Maus Marcela V. Maus Mark B. Leick Mass General Hospital MedNews Week Merle K. Phillips Michael C. Kann OncoDaily Oncology Science Translational Medicine solid cancers Sonika Vatsa Stefanie R. Bailey Tamina Kienka Trisha R. Berger Valentina M. Supper Yan Leyfman

Yvonne Awards 2025: Honoring Global Oncology Leaders at ASCO’s Most Inspiring Night

BEATcc Trial at ESMOGynaec25: Atezolizumab Benefits Cervical Cancer Patients Regardless of PD-L1 Status

15 Posts Not to Miss from EACR 2025

ASCO 2025 RCC Advances: Expert Insights by Ilya Tsimafeyeu

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine